Bioavailability and Controlled Release Symposium Announced by Catalent Applied Drug Delivery Institute

Share Article

The Catalent Applied Drug Delivery Institute today announced that it will host a symposium entitled “Advances in Drug Delivery – Optimal Bioavailability and Controlled Release Solutions for Improved Outcomes”, on September 10th, 2014, at The Palace at Somerset Park, Somerset, NJ, which is near to Catalent’s corporate headquarters.

By sharing best practices and knowledge, we can only succeed in improving the patient experience and bringing novel therapeutics to the market faster.

The Catalent Applied Drug Delivery Institute today announced that it will host a symposium entitled “Advances in Drug Delivery – Optimal Bioavailability and Controlled Release Solutions for Improved Outcomes”, on September 10th, 2014, at The Palace at Somerset Park, Somerset, NJ, which is near to Catalent’s corporate headquarters.

The event will see world-leading experts on drug development and delivery from across industry and academia, including Merck, Catalent Pharma Solutions, Liquidia Technologies, Agere Pharmaceuticals, St John’s University and the University of Mississippi, presenting on a number of key industry topics, including patient-centered drug design, hot melt extrusion, spray drying and overcoming limited bioavailability using lipid-based solutions.

“The Catalent Institute educational symposia are becoming more popular as the Institute continues to grow,” commented Terry Robinson, Executive Director, Catalent Institute. “One of the goals of the Institute is to allow free sharing of ideas and expertise across the industry in a way that has never been done before. By sharing best practices and knowledge, we can only succeed in improving the patient experience and bringing novel therapeutics to the market faster.”

Established in 2012, the Catalent Applied Drug Delivery Institute employs a multi-tiered approach to accelerate the adoption of advanced drug delivery technologies through industry and academic collaboration, research, education, and the sharing of information. In June 2014, the Institute created the Non-Invasive Macromolecule Delivery Consortium (NMDC) as a number of working groups looking at alternative delivery routes to injection for biologics and other large molecule therapeutics.

For more details on the Catalent Institute, visit http://www.drugdeliveryinstitute.com and follow the Catalent Institute on Twitter: @DrugDeliveryIns

About Catalent Applied Drug Delivery Institute

Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments and foster industry collaboration on major issues pertaining to drug development, formulation and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,000 people, including over 1,000 scientists, at 27 facilities across 5 continents. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling

Richard Kerns
Northern Exposure PR
+44 (0) 7974 579202
Email >
Visit website